Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, published by the CMA-Canadian Medical Association, serves as a pivotal platform for disseminating cutting-edge research in the fields of psychiatry and neuroscience. This esteemed journal, indexed with the ISSN 1180-4882 and E-ISSN 1488-2434, focuses on advancing our understanding of mental health through meticulous peer-reviewed articles, reviews, and clinical studies. With an impressive impact within the research community, it has achieved notable rankings, including Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health, as well as Q2 in Biological Psychiatry as of 2023. The journal fosters critical dialogue among scholars and practitioners by offering insights into the complexities of brain function and mental disorders, making it a fundamental resource for healthcare professionals, researchers, and students alike. Although it operates under a subscription model, its rich content continues to inform and influence the advancement of mental health science, affirming its role in bridging the gap between research and clinical practice.

Psychiatria Polska is a distinguished journal published by WYDAWNICZY POLSKIEGO TOWARZYSTWA, focused on advancing the field of psychiatry and mental health. Established in 1967, this journal has become a vital resource for researchers, clinicians, and students, contributing to the understanding of psychiatric disorders and their treatments. With an ISSN of 0033-2674, it features a diverse range of studies, case reports, and reviews, making it an essential platform for sharing innovative findings within the psychiatric community. Although currently categorized in the Q3 quartile for both Medicine (miscellaneous) and Psychiatry and Mental Health in 2023, its increasing impact is evidenced by its Scopus ranking of #345 out of 567 in its category, placing it in the 39th percentile. Located in Cracow, Poland, Psychiatria Polska continues to foster international collaboration and knowledge exchange, despite being non-open access, ensuring that its high-quality content reaches a wide audience. This journal is dedicated to enhancing the dialogue on mental health, making it an indispensable resource for those committed to improving psychiatric practice and research.

Current Behavioral Neuroscience Reports, published by SPRINGERNATURE, stands at the forefront of advancements in the intricate field of behavioral neuroscience. Since its inception in 2014, this journal has steadily garnered attention within academic circles, boasting a commendable ranking among its peers, including a Q3 classification in Behavioral Neuroscience and a Q2 classification in Public Health, Environmental and Occupational Health as of 2023. Although it operates under traditional access models, the journal is committed to disseminating high-quality research that bridges the gap between neuroscience and behavioral studies, appealing to researchers, professionals, and students alike. With a notable E-ISSN of 2196-2979, Current Behavioral Neuroscience Reports facilitates valuable insights that are critical for understanding the underlying mechanisms of behavior and their implications for public health and environmental factors. This journal is essential for those seeking to contribute to a multidisciplinary dialogue that enhances our comprehension of behavioral neuroscience.

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

EUROPEAN PSYCHIATRY, published by Cambridge University Press, stands at the forefront of advancements in the field of psychiatry and mental health, serving as a vital resource for researchers, professionals, and students alike. With an impressive Q1 ranking in Psychiatry and Mental Health and an impact factor that underscores its significance, this journal fosters innovative studies and discussions that shape contemporary understanding of mental health issues. Offering Open Access since 2020, it ensures that high-quality research is readily available to a global audience, bridging gaps in knowledge dissemination. The journal, which has been publishing since 1991, encompasses a broad range of topics relevant to mental health, emphasizing evidence-based practices and interdisciplinary approaches to treatment and care. With its ongoing commitment to excellence, EUROPEAN PSYCHIATRY continues to be an indispensable platform for advancing the science of mental health.

Basic and Clinical Neuroscience, published by Iran University of Medical Sciences, is a distinguished open-access journal that has been operational since 2009, providing a platform for the dissemination of significant research in the fields of neuroscience and neurology. With the ISSN 2008-126X and E-ISSN 2228-7442, this journal serves as a vital resource for researchers, clinicians, and students by facilitating access to the latest findings and advancements in cellular and molecular neuroscience as well as clinical neurology. Although currently rated in Q4 for Cellular and Molecular Neuroscience and Q3 for Clinical Neurology as of 2023, it aims to enhance its standing through the publication of high-quality, peer-reviewed research. The journal has achieved a Scopus rank placing it in the 38th percentile for Neurology and the 13th percentile for Neuroscience, indicating a growing recognition of its contributions. With its commitment to open access, Basic and Clinical Neuroscience not only contributes to the scientific community in Iran but also strives to connect researchers worldwide, fostering collaborative efforts in tackling complex neurological challenges.

BMC Psychiatry is a leading open-access journal published by BMC, dedicated to advancing the field of psychiatry and mental health. With its E-ISSN 1471-244X, the journal has been at the forefront of disseminating high-quality research since its inception in 2001, and it proudly maintains a Q1 ranking among psychiatry and mental health journals, reflecting its significant impact and relevance within the research community. Based in the United Kingdom, BMC Psychiatry boasts a commendable Scopus ranking of #158 out of 567 in the psychiatry and mental health category, placing it in the 72nd percentile. The journal serves as a vital platform for scholars, clinicians, and students alike, providing them with access to groundbreaking studies, innovative methodologies, and emerging trends in mental health. By fostering a collaborative environment, BMC Psychiatry not only enriches the academic landscape but also contributes to evidence-based practice and policy in mental health care.